Cannabinoids MarketSize, Share & Industry Analysis, 2026-2034By Cannabinoid TypeBy SourceBy Product FormBy Extraction MethodBy ApplicationBy Spectrum ProfileBy Purity GradeBy Route of AdministrationBy Distribution ChannelBy Legal Status

Cannabinoids are the active compounds of the cannabis and hemp plants, supplied as isolated molecules, distillates and extracts, or produced by chemical synthesis and fermentation. They are sold as pharmaceutical ingredients and approved drugs, as nutraceutical and cosmetic ingredients, and as finished consumer products such as oils, capsules, edibles, topicals and inhalables. Buyers include drug makers, supplement and beverage brands, personal care companies, licensed retailers, pharmacies and patients under medical programmes.

The global cannabinoids market stood at USD 36 billion in 2025. A forecast-period rate of 13.59% takes it to USD 113.6 billion by 2034, and the study reports every year in between, passing USD 17 billion in 2020, USD 31.8 billion in 2024, USD 41 billion in 2026 and USD 69.2 billion in 2030.

55% of 2025 revenue sits in Cannabidiol (CBD), worth USD 19.8 billion and rising to USD 52.26 billion at 46% by 2034, the largest cannabinoid type line in both years. Growth is fastest in Cannabigerol (CBG) at 22.97% and slowest in Cannabidiol (CBD) at 11.33%. Share moves toward Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC) and Cannabidiolic Acid (CBDA) and away from Cannabidiol (CBD), Tetrahydrocannabinol (THC) and Other Cannabinoids, though no line shrinks in revenue terms.

By source, Hemp-Derived accounts for 48% of 2025 revenue at USD 17.28 billion, reaching USD 52.26 billion and 46% by 2034. Synthetic grows faster at 19.92% against 13.09%, moving from 8% of revenue to 13% by 2034. This axis divides the same revenue as the cannabinoid type split instead of adding to it, so the two are read together and never summed.

Geographically, 40% of 2025 revenue sits in North America (USD 14.4 billion rising to USD 38.62 billion) ahead of Europe at 25% and USD 9 billion. Middle East and Africa is smallest, at 7%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

Coverage extends to five regions, seven cannabinoid type lines and ten segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 36 billion in 2025 to USD 113.6 billion in 2034, a compound annual rate of 13.59%, having reached USD 31.8 billion in 2024 from USD 17 billion in 2020.
• Cannabidiol (CBD) is the largest cannabinoid type line at USD 19.8 billion in 2025, a 55% share, reaching USD 52.26 billion and 46% of revenue by 2034.
• At 22.97%, Cannabigerol (CBG) grows faster than any other cannabinoid type line, moving from USD 1.44 billion and 4% of revenue in 2025 to USD 9.66 billion and 8.5% in 2034.
• Scenario range for 2034 runs from USD 82.6 billion in the bear case to USD 132 billion in the bull case, against a base-case USD 113.6 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 14.4 billion in 2025 (40% of the global total) and USD 38.62 billion by 2034, ahead of Europe at 25%.
• The United States accounts for 87.5% of North America in the base year, worth USD 12.6 billion in 2025 and reaching USD 33.5 billion by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and ten segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three things move over 2026-2034, and they are worth separating: the cannabinoid type mix, the regional balance, and the 13.59% compounding underneath both.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Cannabigerol (CBG) grows at more than twice the pace of Cannabidiol (CBD). Cannabigerol (CBG) grows at 22.97% across 2026-2034 against 11.33% for Cannabidiol (CBD), the widest spread on the cannabinoid type axis. Shares follow: 4% to 8.5% for Cannabigerol (CBG), 55% to 46% for Cannabidiol (CBD). The revenue figures behind that are USD 1.44 billion to USD 9.66 billion and USD 19.8 billion to USD 52.26 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 20% of revenue in 2025 to 26% in 2034, worth USD 7.2 billion rising to USD 29.54 billion; Latin America moves from 8% of revenue in 2025 to 9% in 2034, worth USD 2.88 billion rising to USD 10.22 billion. The offsetting side is North America at 40% moving to 34%, Europe at 25% moving to 24%, Middle East and Africa at 7% moving to 7%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

The series never breaks trajectory. Fifteen years of revenue run USD 17 billion in 2020, USD 31.8 billion in 2024, USD 36 billion in 2025, USD 41 billion in 2026, USD 69.2 billion in 2030 and USD 113.6 billion in 2034. Against 16.19% through the historical period, the 13.59% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the cannabinoid type and regional axes, not by the headline rate.

Cannabigerol (CBG) carries the market's growth rate

The 13.59% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the cannabinoid type axis, and where regional growth is concentrated.

The bear case and what drives it

Upside case: USD 132 billion by 2034

One cannabinoid type line carries the market

In North America, 40% of global revenue puts 2025 at USD 14.4 billion on the way to USD 38.62 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 34%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Cannabidiol (CBD) leads here as it does globally, at 55% of 2025 revenue, and Cannabigerol (CBG) again grows fastest at 22.97%. Per-axis and per-country detail for North America sits in the full report.

87.5% of North America's base-year revenue comes from the United States; USD 12.6 billion, rising to USD 33.5 billion by 2034. Carrying 87.5% of the region in the base year, it sets North America's direction instead of merely contributing to it. Against regional totals of USD 14.4 billion in 2025 and USD 38.62 billion in 2034, it is the country the full report breaks out in detail.

The cannabinoid type pattern in the United States is the global one: 55% of 2025 revenue in Cannabidiol (CBD), 46% by 2034, against 22.97% growth in Cannabigerol (CBG) taking it from 4% to 8.5%. Since 87.5% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The United States carries its own cannabinoid type breakdown in the full report.

Cannabinoid products in the United States fall under the Food and Drug Administration and, for scheduling, the Drug Enforcement Administration. Hemp-derived cannabidiol was removed from the controlled substances schedule by the Agriculture Improvement Act, yet the FDA does not accept it as a dietary ingredient or conventional food additive, and it bars therapeutic claims on unapproved products. Pharmaceutical cannabinoids need a new drug application with clinical evidence and manufacturing under good manufacturing practice. Marijuana-derived material stays federally controlled, so suppliers also face state licensing, testing and labelling rules that differ by jurisdiction.

Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc. are the suppliers covered in the United States. Two different problems sit on the same axis: holding Cannabidiol (CBD) at 55% of 2025 revenue, and taking Cannabigerol (CBG) while it grows at 22.97%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 1.5 billion in 2025, rising to USD 4.4 billion by 2034; 4.17% of global revenue and 10.42% of North America. It is reported separately from the United States across every segmentation axis in the full report.

25% of the global cannabinoids market sits in Europe in 2025, worth USD 9 billion and reaches USD 27.26 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

24% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The cannabinoid type mix reported at global level applies here, with Cannabidiol (CBD) the largest line at 55% of 2025 revenue and Cannabigerol (CBG) the fastest-growing at 22.97%. Per-axis and per-country detail for Europe sits in the full report.

The largest single market in Europe is Germany, at USD 2.7 billion in 2025 and USD 8.4 billion in 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 9 billion in 2025 and USD 27.26 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Cannabidiol (CBD) at 55% of 2025 revenue, easing to 46% by 2034, and the fastest is Cannabigerol (CBG) at 22.97%, from 4% to 8.5%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by cannabinoid type for Germany is reported separately in the full report.

In Germany, medicinal cannabis is overseen by the Federal Institute for Drugs and Medical Devices (BfArM), which also runs the national cannabis agency for cultivation under state control. Following the reform of the medical cannabis law, flowers and extracts are prescription medicines dispensed through pharmacies, with supply governed by good manufacturing and good distribution practice. Cannabidiol sold as food or a supplement is treated as a novel food under European Union rules and needs authorisation from the European Commission, based on EFSA assessment. Labelling must follow medicines or food law depending on the route, and suppliers need the appropriate import or manufacturing licences.

Competition in Germany runs between the suppliers this study tracks: Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.. Two different problems sit on the same axis: holding Cannabidiol (CBD) at 55% of 2025 revenue, and taking Cannabigerol (CBG) while it grows at 22.97%. A supplier weighted toward Europe is competing over a base of USD 9 billion in 2025, reaching USD 27.26 billion by 2034 on the trajectory this study models.

Within Europe, the United Kingdom accounts for 25% of regional revenue and 6.25% of the global total, worth USD 2.25 billion in 2025 and USD 6.5 billion by 2034.

Switzerland is sized at USD 1.35 billion in 2025, rising to USD 3.9 billion by 2034; 3.75% of global revenue and 15% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

20% of the global cannabinoids market sits in Asia Pacific in 2025, worth USD 7.2 billion with USD 29.54 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

26% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 13.59%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Cannabidiol (CBD) largest at 55% of 2025 revenue, Cannabigerol (CBG) fastest at 22.97%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

31.94% of Asia Pacific's base-year revenue comes from China; USD 2.3 billion, rising to USD 9.8 billion by 2034. At 31.94% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 7.2 billion in 2025 and USD 29.54 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

China buys along the same lines as the market globally; Cannabidiol (CBD) first at 55% of 2025 revenue and 46% in 2034, Cannabigerol (CBG) fastest at 22.97% on a share moving from 4% to 8.5%. Since 31.94% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by cannabinoid type separately.

China regulates cannabinoids through the National Medical Products Administration for drugs and the Ministry of Public Security for narcotics control. Cannabis is a controlled substance, and tetrahydrocannabinol is tightly restricted. Industrial hemp cultivation is permitted in designated provinces under local licensing for fibre and seed, while cannabidiol extraction for export is allowed in limited settings. Cannabidiol is not authorised as an ingredient in food, and the cosmetics regime run by the same drug authority has historically allowed it only in registered products meeting safety assessment. Pharmaceutical cannabinoids require clinical trial approval and marketing registration, with Chinese-language labelling.

The suppliers tracked in this study (Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.) compete in China across the cannabinoid type lines above. The commercially relevant division is 55% of 2025 revenue in Cannabidiol (CBD), where the volume is, against 22.97% growth in Cannabigerol (CBG), where share moves. A supplier weighted toward Asia Pacific is competing over a base of USD 7.2 billion in 2025 reaching USD 29.54 billion by 2034, 20% of global revenue at the start of that period.

Australia is sized at USD 1 billion in 2025, rising to USD 4 billion by 2034; 2.78% of global revenue and 13.89% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Japan is sized at USD 0.9 billion in 2025, rising to USD 3.2 billion by 2034; 2.5% of global revenue and 12.5% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

USD 2.88 billion of 2025 revenue is generated in Latin America, 8% of the global cannabinoids market and reaches USD 10.22 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 9% by 2034, at a pace above the 13.59% global rate, so this region warrants separate treatment and should not be scaled off the total.

Segment composition follows the global pattern: Cannabidiol (CBD) largest at 55% of 2025 revenue, Cannabigerol (CBG) fastest at 22.97%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 1.1 billion in 2025 and USD 4 billion in 2034. 38.19% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 2.88 billion to USD 10.22 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Cannabidiol (CBD) first at 55% of 2025 revenue and 46% in 2034, Cannabigerol (CBG) fastest at 22.97% on a share moving from 4% to 8.5%. Because the country carries 38.19% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Brazil by cannabinoid type separately.

In Brazil, the national health surveillance agency, ANVISA, regulates cannabinoid products. A dedicated resolution created a pathway for manufacturing and importing cannabis-based products, which are authorised for sale in pharmacies on prescription and are not registered as full medicines. Suppliers must hold sanitary authorisation, meet good manufacturing practice, and provide quality control data, including cannabinoid content limits for tetrahydrocannabinol. Patients may also import products individually under a separate procedure. Domestic cultivation remains largely prohibited outside court-granted exceptions. Labelling must state composition, concentration and prescription requirements in Portuguese, and registered medicines follow the standard drug approval route.

Competition in Brazil runs between the suppliers this study tracks: Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.. The commercially relevant division is 55% of 2025 revenue in Cannabidiol (CBD), where the volume is, against 22.97% growth in Cannabigerol (CBG), where share moves. A supplier weighted toward Latin America is competing over a base of USD 2.88 billion in 2025, reaching USD 10.22 billion by 2034 on the trajectory this study models.

Colombia is sized at USD 0.8 billion in 2025, rising to USD 2.8 billion by 2034; 2.22% of global revenue and 27.78% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Within Latin America, Mexico accounts for 19.1% of regional revenue and 1.53% of the global total, worth USD 0.55 billion in 2025 and USD 2 billion by 2034.

USD 2.52 billion of 2025 revenue is generated in Middle East and Africa, 7% of the global cannabinoids market on the way to USD 7.95 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Share settles at 7% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Cannabidiol (CBD) leads here as it does globally, at 55% of 2025 revenue, and Cannabigerol (CBG) again grows fastest at 22.97%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Israel, at USD 0.85 billion in 2025 and USD 2.7 billion in 2034. Its 33.73% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Regional revenue of USD 2.52 billion in 2025 and USD 7.95 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Israel buys along the same lines as the market globally; Cannabidiol (CBD) first at 55% of 2025 revenue and 46% in 2034, Cannabigerol (CBG) fastest at 22.97% on a share moving from 4% to 8.5%. Because the country carries 33.73% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-cannabinoid type revenue for Israel appears on its own in the full report.

Israel regulates medical cannabis through the Ministry of Health, historically via its dedicated medical cannabis unit, now moving toward treatment as a standard pharmaceutical regime. Growers, manufacturers and distributors need licences, and products must conform to good agricultural practice and good manufacturing practice standards. Physicians prescribe under specified indications, and patients obtain supply through licensed pharmacies. Exporters need additional approval from the Ministry of Health and the relevant agencies, and destination countries impose their own import rules. Labelling must identify the strain or product type, cannabinoid composition and batch, and quality testing at accredited laboratories is mandatory before release.

Competition in Israel runs between the suppliers this study tracks: Jazz Pharmaceuticals plc, Canopy Growth Corporation, Tilray Brands, Inc., Charlotte's Web Holdings, Inc., Aurora Cannabis Inc., Curaleaf Holdings, Inc., Cresco Labs Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Mile High Labs, Inc., Medterra CBD, cbdMD, Inc., Isodiol International Inc., Elixinol Wellness Limited, Folium Biosciences, Cannexus Group, Cannextra, Red Mesa Science & Refining, Big Sky Scientific, Avient Biosciences, Organigram Global Inc., SNDL Inc., Bausch Health Companies Inc., Neuraxpharm Group, Botanix Pharmaceuticals Limited, Zynerba Pharmaceuticals, Inc., Aphria Inc., CV Sciences, Inc., Endoca and Cronos Group Inc.. Two different problems sit on the same axis: holding Cannabidiol (CBD) at 55% of 2025 revenue, and taking Cannabigerol (CBG) while it grows at 22.97%. A supplier weighted toward Middle East and Africa is competing over a base of USD 2.52 billion in 2025 reaching USD 7.95 billion by 2034, 7% of global revenue at the start of that period.

South Africa is sized at USD 0.65 billion in 2025, rising to USD 2.1 billion by 2034; 1.81% of global revenue and 25.79% of Middle East and Africa. It is reported separately from Israel across every segmentation axis in the full report.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by cannabinoid type, source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel, legal status, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.